[sarah]

Greg, you state: "
The only problem I see is that these assays are labor intensive, non-proprietary (public domain) and there is absolutely no support from either private sector investors or clinical trialists (who receive generous support from pharmaceutical sponsors but who can be given absolutely no support from the particular laboratory). This has always been the problem. It's an orphan technology."
Well that's the crux of the problem, can't make money off it, why do it. If all the fundraisers for different cancers (such as Komen, etc) could be persuaded to fund such a trial, that would be great.
How could we go about it? Still it does have benefit to the insurance companies so they should be for it also.
Sarah